A warning has been issued by Tibotec, the manufacturers of Prezista (darunavir) regarding the risk of developing drug- induced hepatitis while taking the treatment.

While newer antiretrovirals do not appear to cause lipoatrophy, the disfiguring side effect characterised by loss of fat from the face and limbs, the problem is still very much with us. David Menadue examins the latest research and treatments.

The annual conference of the Australasian Society for HIV Medicine (ASHM) was held in Melbourne in November. This article summarises some key developments.

An ATPA fact sheet on Lipoatrophy – the loss or ‘wasting’ of fat from the face, as well as sometimes the buttocks, upper arms legs or thighs. Options for prevention, treatment and management of fat loss associated with HIV treatments.

The sudden cancellation of a large HIV clinical study has significant implications for how we treat HIV. KIRSTY MACHON reports.

!(thumbnail)/files/atpafs_arv_thumb.jpg( )! This ATPA fact sheet is a quick reference to the factors people with HIV and their doctors need to consider when choosing an antiretroviral treatment regimen.

The beautiful beaches of Rio de Janeiro are hardly the place in which you’d imagine your thoughts would start turning to mortality, but for a while there not even the incredible, hunky, tanned Adonises strutting before me could distract me from thoughts of impending doom.

The annual Retrovirus Conference is a key event on the HIV scientific calendar, and regularly highlights the most exciting ‘bleeding edge’ developments from the world of HIV science.

With major medical conferences in the United States and Scotland, November was a busy month for HIV medicine. PAUL KIDD reviews some key findings.

The Sixth International Workshop on Lipodystrophy and Adverse Events was held in Washington DC, USA, from 25 to 28 October 2004. NAPWA’s HIV Health Policy Officer, Kirsty Machon, attended the workshop and has filed a detailed report.